CompletedNCT00318539
Quetiapine added to treatment for OCD
About this title
Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study
Read the official source — NCT00318539Medication studyAges 18–70Netherlands
Understand this study
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- UtrechtSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateDecember 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 90
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Netherlands
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00318539
- Official title
Show the full official title
Quetiapine Augmentation to SRIs for Patients With Obsessive Compulsive Disorder, a Double-blind, Placebo-controlled Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedUtrecht
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine.
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
